No Data
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm With SOD2 MRNA Delivered by SemaPhore Nanoparticles
Express News | Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm With Sod2 Mrna Delivered by Semaphore Nanoparticles
Altamira Therapeutics | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Altamira Therapeutics Ltd. is about to merge its two Basel (Switzerland) subsidiaries Auris Medical AG and Altamira Therapeutics AG
Altamira Therapeutics Ltd. is about to merge its two Basel (Switzerland) subsidiaries Auris Medical AG and Altamira Therapeutics AG
Altamira Therapeutics Ltd — the merged entity will be named Altamira Therapeutics AG and will continue to be the company's core operating subsidiary
Altamira Therapeutics Ltd — the merged entity will be named Altamira Therapeutics AG and will continue to be the company's core operating subsidiary
No Data